Riskpilot← Back to searchSign inGet full accessAitoPharma Oy
OYActiveY-tunnus 3089228-1Kulovalkeankuja 4-N42Other human health activities · NACE 8690Est. 2019— employeeswww.aitopharma.fi
Revenue 2022
—
EBITDA margin
—
-48% vs 2021
Equity ratio
89.6%
Financial strength
Net profit 2022
EUR -1K
-47% vs 2021
| Revenue | — | — |
| EBITDA | EUR -1K | -48% |
| Net profit | EUR -1K | -47% |
| Total assets | EUR 3K | -18% |
| Equity | EUR 3K | -26% |
| Employees | — | — |
Legal name
AitoPharma Oy
Y-tunnus number
3089228-1
Legal form
Osakeyhtiö
NACE code
8690 · Other human health activities
Founded
23. syyskuuta 2019
Share capital
EUR 1 000
Employees
—
VAT registered
No
Audit selected
No
Last report
2022-09-30
Financial year
January – December
Signatory rights
Selvitystilan aikana selvitysmies yksin
Company purpose
Potilas- ja lääkitysturvallisuuden ja rationaalisen lääkehoidon ohjaamiseen, kehittämiseen ja toteuttamiseen liittyvien asiantuntija-, koulutus- ja konsultointipalveluiden sekä ohjelmisto- ja teknologiaratkaisujen kehittäminen, tuottaminen ja myynti sekä aiheeseen liittyvä tutkimus, muiden farmaseuttisten palveluiden tuottaminen ja myynti sekä muu aiheeseen läheisesti liittyvä toiminta.
Yhtiö voi omistaa, ostaa ja myydä arvopapereita, osakkeita, osuuksia ja oikeuksia kotimaassa ja ulkomailla sekä harjoittaa sijoitustoimintaa.
Address
Kulovalkeankuja 4-N42
Phone
+358405784791
Email
tiina.koskenkorva@aitopharma.fi
Website
www.aitopharma.fi
Risika for professionals
Risika provides regulated workflow tools for finance, procurement and compliance teams that need monitoring, alerts and an API.
| Item | 2020 | 2021 | 2022 |
|---|---|---|---|
| Revenue | 20 | 0 | — |
| Staff expenses | −13 | — | — |
| EBITDA | 5 | −1 | −1 |
| Depreciation & amort. | — | — | — |
| EBIT | 5 | −1 | −1 |
| Net financials | −0 | −0 | 0 |
| Profit before tax | 5 | −1 | −1 |
| Tax | 1 | −0 | −0 |
| Net profit | 4 | −1 | −1 |
| Item | 2020 | 2021 | 2022 |
|---|---|---|---|
| Total assets | 6 | 4 | 3 |
| Equity | 5 | 4 | 3 |
| Long-term debt | — | — | — |
| Short-term debt | 1 | 0 | 0 |
| Total debt | 1 | 0 | 0 |
EBITDA margin
-108500.0%
This company
15.8%
Market median
-686809% vs market
20202022
Equity ratio
89.6%
This company
38.2%
Market median
+135% vs market
20202022
Return on equity
-36.0%
This company
18.4%
Market median
-296% vs market
20202022
Net profit margin
-108500.0%
This company
8.1%
Market median
-1339606% vs market
20202022
Asset turnover
0.00×
This company
1.12×
Market median
-100% vs market
20202022
Debt / equity
0.12×
This company
0.62×
Market median
+81% vs market
20202022
| Name | Role | Member since |
|---|---|---|
| Current (1) | ||
AL Liquidator | Liquidator | 2022 |
| Former (1) | ||
TH Chief Executive Officer | Chief Executive Officer | 2019 – 2022 |
| Name | Role | Member since |
|---|---|---|
| Former (2) | ||
| Board of Directors | 2019 – 2022 | |
| Board of Directors | 2019 – 2022 | |
No shareholder data available.
Beneficial ownership (UBO) data access is restricted in Denmark as of September 2025 per the EU 6th AML Directive. Learn more.
No registered parent or subsidiaries
Board members of AitoPharma Oy also hold positions in 0 other companies.
| Person | Role here | Other companies |
|---|---|---|
| Tiina Hannele Koskenkorva | Chief Executive Officer | 0 companies |
| Anu Lotta Pauliina Issakainen | Liquidator | 0 companies |
| Juho Ilmari Koskenkorva | Board of Directors | 0 companies |
| Mikko Juhani Koskenkorva | Board of Directors | 0 companies |